{
    "clinical_study": {
        "@rank": "72281", 
        "arm_group": [
            {
                "arm_group_label": "Group A. L-PPDS single occlusion", 
                "arm_group_type": "Experimental", 
                "description": "Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks."
            }, 
            {
                "arm_group_label": "Group B. L-PPDS double occlusion", 
                "arm_group_type": "Experimental", 
                "description": "Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks."
            }, 
            {
                "arm_group_label": "Group C. L-PPDS re-insertion", 
                "arm_group_type": "Experimental", 
                "description": "Latanoprost Punctal Plug Delivery System (L-PPDS) re-insertion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye; The L-PPDS will remain for a period of 12 weeks. At Week 12, after the final intraocular pressure (IOP) measurement, the L-PPDS will be replaced and will remain for two weeks."
            }, 
            {
                "arm_group_label": "Group D. Timolol Maleate GFS, 0.5%", 
                "arm_group_type": "Active Comparator", 
                "description": "Timolol Maleate GFS drops; One drop timolol maleate ophthalmic GFS 0.5% QAM for 14 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Compare efficacy of the latanoprost punctal plug to timolol maleate ophthalmic gel forming\n      solution (GFS) 0.5% (administered once every morning). Effect of configuration of L-PPDS\n      placement and re-insertion of L-PPDS on efficacy will also be examined."
        }, 
        "brief_title": "Comparison of Latanoprost PPDS With Timolol Maleate GFS in Subjects With Ocular Hypertension or Open-Angle Glaucoma", 
        "condition": [
            "Ocular Hypertension", 
            "Open-Angle Glaucoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, 18 years or older at the time of the screening examination\n\n          2. Subject diagnosed with bilateral OAG or OH\n\n          3. Subject IOP is currently controlled (< 21 mmHg) with a topical prostaglandin or in\n             conjunction with one other topical ocular hypotensive drug, not including any\n             fixed-combination formulations (i.e., Cosopt, Combigan, Azarga, etc.) for at least\n             one month or more\n\n          4. Subject who has lower and upper puncta > 0.5 mm and < 0.9 mm (pre-dilation) in both\n             eyes\n\n          5. Subject must be able and willing to read, comprehend and give Authorization for\n             Use/Disclosure of Health Information (HIPAA) and informed consent\n\n          6. Subject must be willing to comply with study instructions, dosing (if applicable),\n             agree to make all office appointments, and complete the entire course of the study\n\n          7. Women of child-bearing potential must not be pregnant or lactating, must have a\n             negative pregnancy test at screening and must be practicing an adequate method of\n             birth control, including intrauterine device (IUD); oral, dermal (\"patch\"), implant\n             or injected contraceptives; tubal ligation; or barrier methods with spermicide\n\n          8. Subject has a central corneal thickness of > 500 \u03bcm and < 600 \u03bcm in study eye\n\n          9. Subject has a BCVA or pinhole visual acuity (Snellen) of 20/100 or better in both\n             eyes\n\n        Exclusion Criteria:\n\n          1. Subject with a history of non-response to topical prostaglandin eye drops for OAG/OH\n\n          2. Subject with angle-closure glaucoma, neovascular glaucoma, traumatic glaucoma or\n             iridocorneal endothelium syndrome in either eye\n\n          3. Subject with a known sensitivity to latanoprost, timolol, fluorescein, topical\n             anesthetic, silicone, any inactive ingredient of the L-PPDS or any other products\n             required for the study procedures\n\n          4. Subject with a history of intolerance to topical beta-blocker therapy\n\n          5. Subject with > 0.8 vertical cup or completely notched optic nerve head rim in either\n             eye\n\n          6. Subject with any functionally significant visual field loss or progressive field loss\n             within the last year in either eye\n\n          7. Subject with a history of complications, AEs, trauma or disease in the nasolacrimal\n             area, whether or not it was due to punctal plug wear, including but not limited to\n             dacryocystitis, inflammation or canaliculitis in study eye\n\n          8. Subject with structural lid abnormalities (i.e., ectropion, entropion) in study eye\n\n          9. Subject with an active lid disease in either eye (i.e., moderate or severe\n             blepharitis, meibomianitis) that requires medical treatment\n\n         10. Subject with a history of chronic/recurrent inflammatory eye disease (i.e.,\n             scleritis, uveitis, herpes keratitis) in either eye\n\n         11. Subject who would require the use of any ocular topical medication(s), an over-the\n             counter drop(s), ointment(s) or gel(s), other than the study ocular hypotensive\n             medication(s) in either eye during the study period\n\n         12. Subject who has had any ophthalmic surgical procedures (i.e., glaucoma laser,\n             minimally invasive glaucoma surgery, cataract, refractive, etc.) in study eye within\n             the last six months or will require ophthalmic surgery before completing the study\n\n         13. Subject with a history of penetrating keratoplasty in study eye\n\n         14. Subject who is incapable of instilling ocular drops into his or her eyes\n\n         15. Subject requiring the use of a contact lens in either eye at any time during the\n             study period\n\n         16. Subject with advanced diabetic retinopathy, branch retinal vein occlusion or central\n             retinal vein occlusion in either eye\n\n         17. Subject with a history of macular edema in either eye\n\n         18. Subject currently on any systemic medication [i.e., beta-blocker, carbonic anhydrase\n             inhibitors, corticosteroids (including dermal), etc.], that may have an effect on the\n             subject's IOP, or who will require its use during the study period (Note: an inhaled\n             steroid, systemic beta-blocker or \u03b2-adrenoceptor antagonist may be permitted,\n             providing the subject has maintained a stable dosage regimen for at least the last\n             three months)\n\n         19. Subject contraindicated to therapy with a beta-blocker (i.e., history or presence of\n             bradycardia, untreated congestive heart failure, untreated second- or third-degree\n             heart block, sino-atrial block, myasthenia gravis, cardiogenic shock, history or\n             presence of bronchial asthma, bronchial hyperreactivity, severe chronic obstructive\n             pulmonary disease, or history of bronchospasm)\n\n         20. Subject with an uncontrolled systemic disease or a medical condition that may\n             increase the risk associated with study participation or administration of study\n             treatment or that may interfere with the interpretation of study results (e.g.,\n             autoimmune disease if the subject is on chronic medications and has ocular\n             involvement; host-versus-graft disease)\n\n         21. Subject currently participating or has participated within the last 30 days prior to\n             the start of this study in a drug, device or other investigational research study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02014142", 
            "org_study_id": "PPL GLAU M1"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A. L-PPDS single occlusion", 
                    "Group B. L-PPDS double occlusion", 
                    "Group C. L-PPDS re-insertion"
                ], 
                "description": "Latanoprost Punctal Plug Delivery System (L-PPDS)", 
                "intervention_name": "Latanoprost Punctal Plug Delivery System (L-PPDS)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group D. Timolol Maleate GFS, 0.5%", 
                "description": "Timolol Maleate GFS, 0.5%", 
                "intervention_name": "Timolol Maleate GFS, 0.5%", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Timolol", 
                "Latanoprost", 
                "Maleic acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Damien F. Goldberg, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90505"
                    }, 
                    "name": "Wolstan & Goldberg Eye Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Darrell WuDunn, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana Universtiy - Eugene and Marilyn Glick Eye Institute Ophthalmology Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Edward Holland, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Edgewood", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "41017"
                    }, 
                    "name": "Cincinnati Eye Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Y. Ralph Chu, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bloomington", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55420"
                    }, 
                    "name": "Chu Vision Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gregg Berdy, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63131"
                    }, 
                    "name": "Ophthalmology Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael S. Korenfeld, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63090"
                    }, 
                    "name": "Comprehensive Eye Care, Ltd."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jack Abrams, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89148"
                    }, 
                    "name": "Abrams Eye Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ronald M. Caronia, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lynbrook", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11563"
                    }, 
                    "name": "Ophthalmic Consultants of Long Island"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Steven T. Simmons, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Slingerlands", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12159"
                    }, 
                    "name": "Dr. Steven T. Simmons"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Carolyn Repke, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19148"
                    }, 
                    "name": "Philadelphia Eye Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "L. Jay Katz, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Phildelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Wills Eye Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kenneth W. Olander, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Maryville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37803"
                    }, 
                    "name": "University Eye Surgeons"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eugene B. McLaurin, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38119"
                    }, 
                    "name": "Total Eye Care"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "William Flynn, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Rashid, Rice & Flynn"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2 Single-Masked, Randomized, Parallel Comparison of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Timolol Maleate Ophthalmic Gel Forming Solution 0.5% in Subjects With Ocular Hypertension or Open-Angle Glaucoma", 
        "overall_contact": {
            "email": "brittanybrown@trialrunners.com", 
            "last_name": "Brittany Brown", 
            "phone": "701-483-3599", 
            "phone_ext": "105"
        }, 
        "overall_contact_backup": {
            "email": "bbutchofsky@matitherapeutics.com", 
            "last_name": "Bob Butchofsky"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "IOP change from baseline and the primary analysis time point will be the early morning assessment at Week 12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02014142"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Mati Therapeutics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mati Therapeutics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}